Bioregnum channel feed – Endpoints News

Bioregnum channel feed

Trump’s ‘radical’, ‘horrible’ executive orders on drug pricing earn a C-suite backlash this week — with one threat to do more overseas

5 years ago

The pharma world's champion patent wall builder is called out for their 'drip-feed' strategy to safeguard the next megablockbuster franchise

5 years ago

Antibody legend Tillman Gerngross is elbowing his way into the Covid-19 R&D crusade: 'I don’t see this ending anytime soon'

5 years ago

A neoantigen pioneer says its tech is working great. So what wrecked the share price?

5 years ago

A top analyst turns the spotlight on Moderna, fueling a fast-and-furious Street race over the future of mRNA

5 years ago

Win or lose on the marketing OK, the FDA just gunned down GSK’s bright hopes for their BCMA therapy

5 years ago

The home run count: The $100M+ mega-round boom in biotech inspired a $7.3B feeding frenzy — so far this year

5 years ago

A new study points to $6.5B in public support building the scientific foundation of Gilead's remdesivir. Should that be reflected in the price?

5 years ago

Which drug developers offer Trump a quick, game-changing ‘solution’ as the pandemic roars back? Eli Lilly and AbCellera look to break out of the pack

5 years ago

Positive Covid-19 vaccine data? New mouse study? OWS inclusion? Yep, but somehow, the usual tidbits from Inovio backfire

5 years ago

Day one: The disruptor-in-chief at BridgeBio invites Brent Saunders onto the board

5 years ago

The FDA backs off a hasty — and damaging — emergency OK for a potentially dangerous Covid-19 drug

5 years ago

Cameron Durrant hustled his way from the OTC sidelines right into the Covid-19 drug race. Death or glory lies straight ahead

5 years ago

Sanofi CEO Paul Hudson has $23B burning a hole in his pocket. And here are some hints on how he plans to spend that

5 years ago

Researchers define exactly what they saw in the first positive remdesivir study for Covid-19. But what's that worth to Gilead?

6 years ago

BARDA offers a tiny startup up to $812M to create a US-based drug manufacturer — and the CEO comes with a price gouging controversy on his résumé

6 years ago

Moncef Slaoui pivots from Moderna's board to the helm of Project Warp Speed. His task: Overnight success

6 years ago

BIO gets a new chief lobbyist to face off against the growing ranks of critics in Congress

6 years ago

More than 1,000 clinical trials were stopped by the pandemic — including dozens in PhIII

6 years ago

MacroGenics CEO Scott Koenig gets the pre-ASCO party started with some encouraging pipeline tidbits — leaving lots of questions for later

6 years ago

Full steam ahead, Pfizer goes bargain hunting in an age of coronavirus — with a special focus on cancer and rare diseases

6 years ago

A slice of half-baked remdesivir data takes a dark turn — but we're still waiting for a definitive study

6 years ago

Biogen’s top executive crew has a big credibility issue. And they seem determined to make it worse

6 years ago

Biotech execs warn that the FDA is fumbling their response to the Covid-19 open-door promise, delaying progress

6 years ago

First page Previous page 6 7 8910 11 12 Next page Last page